Anxiety during abstinence in people with alcohol use disorder
Official title: Neural Mechanisms of Anxiety During Early and Protracted Abstinence in Alcohol Use Disorder
Run by Columbia University · NCT06793488 · Data updated 2026-11-12
This project will test whether anxiety and related brain activity change from early to three months of abstinence in people with alcohol use disorder who take disulfiram, compared with healthy volunteers.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 21 Years to 55 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Columbia University Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | September 15, 2025 |
| Main results expected | August 30, 2029 |
| Study ends | August 30, 2029 |
| Registry record updated | February 10, 2026 |
| Trial ID | NCT06793488 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 21–55 seeking treatment for moderate-or-worse AUD who are right-handed, able to consent, willing to take disulfiram, and able to complete two MRI visits.
✕Probably not a fit
People who are pregnant, have MRI contraindications or significant neurological/medical conditions, cannot take disulfiram, or are unwilling to undergo repeated scans are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will recruit 40 people seeking treatment for moderate-or-worse alcohol use disorder and 20 age-matched healthy volunteers. Participants with AUD will be started on disulfiram and undergo fMRI scanning twice—about 8–14 days after their last drink and again after three months of abstinence—while healthy volunteers will have a single fMRI scan. fMRI will include an anxiety-evoking task that probes anticipation of uncertain threat plus resting-state scans to measure connectivity among the anterior insula, bed nucleus of the stria terminalis, and dorsolateral prefrontal cortex. The study will relate changes in circuit activity and connectivity to changes in current anxiety symptoms over abstinence.
Why it matters
Potential benefit: If successful, the findings could identify brain circuit changes that drive abstinence-related anxiety and point to targets for treatments that reduce relapse risk.
How similar studies have gone: Previous fMRI studies have linked the anterior insula, BNST, and DLPFC to anxiety and addiction, but longitudinal imaging across early and protracted abstinence while using disulfiram is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria (Participants with Alcohol use Disorder): 1. Between the ages of 21 and 55 2. Right-handed 3. Able to perform informed consent and comply with study 4. Seeking treatment for AUD 5. Meets The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for AUD of at least moderate severity (\>3 symptoms) Inclusion Criteria (Healthy Volunteer Participants): 1. Between the ages of 21 and 55 2. Right-handed 3. Able to perform informed consent and comply with study 4. Report drinking an average of fewer than 8/15 standard drinks per week for women/men and no more than 1 HDD (heavy drinking days) during the previous 28 days. Exclusion Criteria (Participants with Alcohol use Disorder): 1. Neurological, medical or other conditions that would interfere with MRI scanning (e.g., history of stroke, seizure, brain tumor, brain infection, traumatic brain injury, multiple sclerosis, dementia, non MRI-compliant metal device in body, pregnancy, claustrophobia, color blindness, severe hearing impairment, weight\>300 lbs., wheelchair-bound, tattoos as indicated by the guidelines established by the Zuckerman Institute MRI unit: https://mr.research.columbia.edu/ 2. DSM 5 diagnoses of schizophrenia, schizoaffective disorder, or bipolar disorder 3. Any non-AUD psychiatric disorder that may, according to the investigator's judgment, require treatment over the course of the study 4. Significant suicide or violence risk 5. Currently taking psychotropic medication 6. Current substance use disorder other than AUD, tobacco use disorder or mild cannabis use disorder 7. Currently pregnant, attempting to become pregnant or nursing 8. Sufficiently socially unstable as to preclude participation (e.g. homeless). 9. Known history of allergy, intolerance, or hypersensitivity to disulfiram or its derivates 10. Contraindications to disulfiram treatment (e.g. liver disease, kidney disease, cardiac disease, seizure disorder, hypothyroidism, diabetes mellitus, pregnancy or lactation, allergy to disulfiram or thiuram derivatives) 11. Currently taking medications containing alcohol, metronidazole, isoniazid, paraldehyde, phenytoin, warfarin, or theophylline. 12. Treatment with concomitant medications that might interfere with disulfiram 13. A history of alcohol withdrawal seizures, delirium tremens or resistant alcohol withdrawal 14. Current moderate or severe alcohol withdrawal (CIWA \>9 with BAL\<0.05) 15. History of prior disulfiram treatment failure 16. Being abstinent for \> 7 days at the time of screening Exclusion Criteria (Healthy Volunteer Participants): 1. Neurological, medical or other conditions that would interfere with MRI scanning (e.g., history of stroke, seizure, brain tumor, brain infection, traumatic brain injury, multiple sclerosis, dementia, non MRI-compliant metal device in body, pregnancy, claustrophobia, color blindness, severe hearing impairment, weight\>300 lbs., wheelchair- bound, tattoos as indicated by the guidelines established by the ZI MRI unit: https://mr.research.columbia.edu/ 2. DSM 5 diagnoses of schizophrenia, schizoaffective disorder, or bipolar disorder 3. Any psychiatric disorder that may, according to the investigator's judgment, require treatment over the course of the study 4. Significant suicide or violence risk 5. Currently taking psychotropic medication 6. Current substance use disorder other than tobacco use disorder or mild cannabis use disorder 7. Currently pregnant, attempting to become pregnant or nursing 8. Sufficiently socially unstable as to preclude participation (e.g., homeless). 9. A diagnosis of AUD of any severity
Where it's running
-
Columbia University Irving Medical Center
New York, New York, United States Recruiting
Study contacts
- Study coordinator: A B Srivastava, MD
- Email: abs2257@cumc.columbia.edu
- Phone: 646-774-8189
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures
This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.
-
Thiamine to reduce brain injury in adults with alcohol use disorder
This trial tests whether thiamine can help protect the brain in adults with moderate to severe alcohol use disorder who drink daily.
-
Digital Recovery Support for Black adults with Alcohol Use Disorder in Detroit
This study tests whether a smartphone-based digital recovery program helps Black or African American adults in Detroit maintain their recovery from alcohol use disorder.
-
Path180: a computer-based skills program to help teens reduce alcohol use
This 8-week trial tests Path180, a computer-based skills training, added to usual care for teens 13–19 with alcohol use disorder to see if it improves daily-life coping skills and outcomes.
-
Effects of comorbidity on people with severe mental illness
This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.
-
Psilocybin in Alcohol Use Disorder with Depression (Relapse Prevention)
This study tests whether higher-dose psilocybin-assisted psychotherapy helps prevent relapse in adults with severe alcohol use disorder and depressive symptoms after detox.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.